NHS England has launched a 30 day public consultation on two proposed new clinical commissioning policies for specialised services – specifically Rituximab for the treatment of Primary Sjogren’s Syndrome (PSS) in adults, and Rituximab in Connective Tissue Disease associated Interstitial Lung Disease in adults.
There has already been extensive engagement on these policies. They have been developed with the support and input of lead clinicians and tested with stakeholders. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the policies to date.
Please note this is one of several public consultations on a proposed new draft products for specialised services. We now wish to test them further with wider stakeholders through public consultation.